Updates on therapeutic targets and agents in castration-resistant prostate cancer

Minerva Urologica e Nefrologica

Volumn 63, Issue 2, 2011, Pages 131-143

  Bishr, M ^a,b   Lattouf, J B ^a   Gannon, P O ^a   Saad, F ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

Author keywords

Castration; Neoplasm metastasis; Prostatic neoplasms; Receptors, androgen

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; AFLIBERCEPT; ALKALINE PHOSPHATASE; BEVACIZUMAB; BICALUTAMIDE; CABAZITAXEL; CALCITRIOL; CANCER VACCINE; CUSTIRSEN; CYPROTERONE ACETATE; DENOSUMAB; DOCETAXEL; EPOTHILONE B; ESTRAMUSTINE; FLUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; IXABEPILONE; LENALIDOMIDE; MITOXANTRONE; NILUTAMIDE; ORTERONEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTVAC VF; PROVENGE; SATRAPLATIN; SUNITINIB; TASQUINIMOD; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIBOTENTAN;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; BONE PAIN; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); COLITIS; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TARGETING; DYSPHONIA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOCALCEMIA; INFECTION; JAW OSTEONECROSIS; METASTASIS; MUSCULOSKELETAL PAIN; NAUSEA; NONHUMAN; PROGNOSIS; PROTEINURIA; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SKIN MANIFESTATION; STROKE; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM; VOMITING;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS;

EID: 79960977009     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2011;60:277-300.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. 2010;V2.
3. Sharifi N, Dahut WL, Steinberg SM, Figg WD, Tarassoff C, Arlen P et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int 2005;90:985-9.
4. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
5. Mohler JL, Gregory CW, Ford, OH, 3rd, Kim D, Weaver CM, Petrusz P et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8.
6. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67:5033-41. (Pubitemid 46910214)
7. Fosså SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001;19:62-71.
8. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009;15:4792-8.
9. Tannock IF, Osoba D, Stockier MR, Ernst DS, Neville AJ, Moore MJ et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64. (Pubitemid 26185452)
10. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506-13. (Pubitemid 29368252)
11. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20. (Pubitemid 39315318)
12. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. (Pubitemid 39315317)
13. Winquist E, Waldron T, Berry S, Ernst DS, Hotte S, Lukka H. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. BMC Cancer 2006;6:112.
14. L Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 2010;46:1770-2.
15. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
16. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439-46.
17. Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK et al. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer 2006;106:58-62. (Pubitemid 43033322)
18. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110:556-63. (Pubitemid 47106144)
19. Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC et al. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium. Cancer 2010 (Epub ahead of print].
20. Beardsley EK, Saad F, Eigl B, Venner P, Hotte S, Winquist E et al. A phase II study of patupilone in patients (pts) with metastatic castration- resistant prostate cancer (CRPC) who have progressed after docetaxel. J Clin Oncol 2009;27 (suppl 15; abstr 5139).
21. Têtu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 1987;59:1803-9.
22. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27:5431-8.
23. Zhu W, Zhu DS, Madan RA, Gulley JL, Figg WD, Dahut WL.Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. Am J Ther 2010;17:176-81.
24. Sciarra A, Cardi A, Di Silverio F. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Urol Int 2004;72:91-8. (Pubitemid 38223791)
25. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995;154:1991-8.
26. Potter GA, Barrie SE, Jarman M, Rowlands MG. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995;38:2463-71.
27. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50:267-73. (Pubitemid 24309119)
28. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8.
29. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-501.
30. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:1481-8.
31. de Bono JS. Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer: Phase III results. ESMO 2010.
32. Saad F, de Bono JS, Haqq CM, Logothetis CJ, Fizazi K, Jones RJ et al. Abiraterone acetate plus low-dose prednisone has a favorable safety profile, improves survival and produces psa and radiographic responses in metastatic castration-resistant prostate cancer progressing after docetaxel-based chemotherapy: results from cougar-301, a randomized, double-blind, placebo-controlled, phase zIII study. J Urol 2011;185:e283.
33. Dreicer R, Agus DB, MacVicar GR, Wang J, MacLean D, Stadler M. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A phase I/I I, open-label study. . J Clin Oncol 2010;28 (suppl 15: abstr 3084).
34. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al. Development of a second-generation anti-androgen for treatment of advanced prostate cancer. Science 2009;324:787-90.
35. S Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.
36. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7:1932-6. (Pubitemid 32994827)
37. Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999;161:960-3. (Pubitemid 29422416)
38. Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 2011;117:526-33.
39. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401 J Clin Oncol 2010;28 (suppl 18; Abstr LBA4511).
40. Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007;13:4201-8.
41. Isambert N, Freyer G, Zanetta S, Falandry C, Soussan Lazard K, Fumoleau P. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: Preliminary results. J Clin Oncol 2008;26 (abstr 3599).
42. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115.
43. Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010;21:319-24.
44. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532-9. (Pubitemid 41103740)
45. Petrylak DP, Resto-Garces K, Tibyan M, Mohile SG. A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer. J Clin Oncol 2009;27.
46. Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A et al. A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer (CRPC). J Clin Oncol 2010;28.
47. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-903.
48. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
49. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94. (Pubitemid 46638945)
50. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L Frohlich MW. et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670-9.
51. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009;18:1001-11.
52. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M et al. Overall survival analysis of a phase II randomized controlled trial of a Pox-viral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-105.
53. Antonarakis ES, Carducci MA, Eisenberger MA. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer letters 2010;291:1-13.
54. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007;13:3883-91. (Pubitemid 47037595)
55. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman Met al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008;113:975-84.
56. Higano C, Saad F, Somer B, Curti B, Petrylak D, Drake C. G. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancer Symposium ASCO 2009,(Abstr LBA150).
57. Small E, Demkow T, Gerritsen WR, Rolland F, Hoskin P, Smith DC et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [Internet]. Available from: http://www.asco.org/ascov2/ Meetings/Abstracts?&vmview=abst-detail-view&confID=64&abstractID= 202952009;Abstract #7. [cited 2011, May 3].
58. Chambers CA, Kuhns MS, Egen JG, Allison JP.CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-94.
59. Tollefson MK, Karnes RJ, Thompson RH, Granberg CF, Hillman DW, Breau RH. et al. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer [Internet]. Available from: http://www.asco.org/ascov2/Meetings/Abstracts? &vmview=abst-detail-vicw&confID=73&abstractID=308972010 [cited 2011, May 31.
60. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000;60:170-6. (Pubitemid 30058748)
61. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. The Prostate 2002;50:179-88. (Pubitemid 34137445)
62. Saad F, Hotte SJ, North SA, Eigl B, Chi K, Czaykowski P et al. A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer who relapsed on or within six months of 1st-line docetaxel therapy. Can Urol Assoc J 2008;2:568.
63. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010:4247-54.
64. Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer research 2004;64:8620-9. (Pubitemid 39552075)
65. Higano C, Alumkal J, Ryan CJ, Yu EY, Beer TM, Chandrawansa K. et al. A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastastic, asymptomatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2009;27 (Suppl 15; Abstr 5142).
66. Akhavan A, McHugh KH, Guruli G, Bies RR, Zamboni WC, Strychor SA et al. Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia 2006;8:725-32.
67. Nelson JH, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-9.
68. Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale JL et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003;100:10954-9. (Pubitemid 37140134)
69. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 2002;20:2171-80. (Pubitemid 34408809)
70. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110:1959-66. (Pubitemid 350036854)
71. Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008;113:2478-87.
72. James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU international 2010;106:966-73.
73. P Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994;54:805-10. (Pubitemid 24068341)
74. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25:669-74. (Pubitemid 350002922)
75. Scher HI, Chi KN, De Wit R, Berry WR, Albers P, Henick B et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial. J Clin Oncol 2010;28.
76. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579.
77. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892-9. (Pubitemid 38222847)
78. P Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis 2002;5:304-10. (Pubitemid 36124442)
79. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-55.
80. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-12. (Pubitemid 36576705)
81. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82. (Pubitemid 38807610)
82. Ullén A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kälkner KM, Lennernäs B et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005;44:644-50.
83. Saad F, Markus R, Goessl C. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases. HJU Int 2008;101:1071.
84. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22.
85. Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int 2009;103:434.
86. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9. (Pubitemid 41507982)
87. Araujo J, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086). J Clin Oncol 2009;27.